Abstract
The most abundant microRNA (miRNA) in the liver, miR-122, is regulated by specific, liver-enriched transcription factors and is responsible for proper proliferation and differentiation of hepatocytes and for the regulation of lipid and cholesterol metabolisms. miR-122 is also involved in several hepatic disorders, as downregulation of miR-122 is often associated with hepatocellular carcinoma (HCC) and miR-122 is a required component for the replication and proliferation of the hepatitis C virus (HCV). Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors. These agents, capable of specifically modifying miR-122 activity, provide excellent tools to investigate the function and regulation of miR-122 and offer potential new lead compounds for drug discovery. Especially small molecule modifiers can display numerous advantages over nucleotide analogs, as discussed in this review.
Keywords: miRNA-122, liver disorders, miRNA therapeutics, small molecules, antisense oligonucleotides, antagomirs, hepatitis C virus, hepatocellular carcinoma, lipid and cholesterol metabolism, regulation of miRNA function.
Current Medicinal Chemistry
Title:MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Volume: 20 Issue: 29
Author(s): M. Thomas and A. Deiters
Affiliation:
Keywords: miRNA-122, liver disorders, miRNA therapeutics, small molecules, antisense oligonucleotides, antagomirs, hepatitis C virus, hepatocellular carcinoma, lipid and cholesterol metabolism, regulation of miRNA function.
Abstract: The most abundant microRNA (miRNA) in the liver, miR-122, is regulated by specific, liver-enriched transcription factors and is responsible for proper proliferation and differentiation of hepatocytes and for the regulation of lipid and cholesterol metabolisms. miR-122 is also involved in several hepatic disorders, as downregulation of miR-122 is often associated with hepatocellular carcinoma (HCC) and miR-122 is a required component for the replication and proliferation of the hepatitis C virus (HCV). Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors. These agents, capable of specifically modifying miR-122 activity, provide excellent tools to investigate the function and regulation of miR-122 and offer potential new lead compounds for drug discovery. Especially small molecule modifiers can display numerous advantages over nucleotide analogs, as discussed in this review.
Export Options
About this article
Cite this article as:
Thomas M. and Deiters A., MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules, Current Medicinal Chemistry 2013; 20 (29) . https://dx.doi.org/10.2174/0929867311320290009
DOI https://dx.doi.org/10.2174/0929867311320290009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
Current Medicinal Chemistry Novel Molecular Anti- Colorectalcancer Conjugate:Chlorambucil-Adipic Acid Dihydrizide-Glutamine
Anti-Cancer Agents in Medicinal Chemistry STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medicinal Chemistry The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry A Solvent-free Method for Synthesis of Dihydroangelicins using Microwaves
Current Green Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine Novel Artemisinin-Derived Dimers: Synthesis and Evaluation of Anti-cancer Activities
Letters in Drug Design & Discovery Contrast Enhanced Ultrasonography for Focal Liver Lesions Characterization: Clinical Perspective
Current Medical Imaging Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry